Dominic D'Agostino

But NAD is sort of like this hub that is a central player in the benefits of ketogenesis.

I can't say what I'm doing now, but we're running experiments, I think, even today.

So there's different NAD molecules that are out that are stabilized forms of them that are in clinical trials.

I think phase two and maybe phase three clinical trials.

It's a stabilized, you have to stabilize NAD.

And I think that's important to have it stabilized because when you consume it, the liver takes a lot of it.

And if it doesn't, you're not taking enough of it in a stabilized form, the liver is very greedy.

Actually, I think it'd be good for non-alcoholic fatty liver disease.

So that's another, I think NAD could be important for that.

But I think you have to take a dose that gets past the liver into circulation and crosses the blood-brain barrier.

And there's a number of different stabilized versions of NAD that are in development and testing, and some of them we're working on, that I think have potential for oxygen toxicity.

So we're working on those now, giving acutely and also chronically in graded doses.

I am convinced that some of the animal literature, I want to replicate it.

So I'm not going to believe something until I replicate it.

So I think we have plans to do some exercise studies, oxygen toxicity brain studies.

So I do think that you need to give quite a bit of it in a stabilized form and it needs to get to the muscle.

And for me, I'm very interested in crossing the blood brain barrier and getting to the brain.

I also think that these things will be more efficacious in the context of energetic metabolic stress.

So for someone who's already aged, where your NAD level tanks and goes down in a linear fashion, like with age, NAD goes down, but also in the context of traumatic brain injury or shock.

And these are the things that we study.